Bio-Techne financials
$72.38−0.18%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Jun 30 | FY25 Jun 30 | FY24 Jun 30 | FY23 Jun 30 | FY22 Jun 30 | FY21 Jun 30 | FY20 Jun 30 | FY19 Jun 30 | FY18 Jun 30 | FY17 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.22B | $1.22B | $1.16B | $1.14B | $1.11B | $931.0M | $738.7M | $714.0M | $643.0M | $563.0M |
| Gross profit | $799.1M | $790.3M | $769.7M | $769.8M | $756.5M | $632.9M | $483.2M | $473.5M | $432.1M | $374.5M |
| Gross margin | 65.8% | 64.8% | 66.4% | 67.7% | 68.4% | 68.0% | 65.4% | 66.3% | 67.2% | 66.5% |
| Operating income | $251.9M | $102.3M | $206.7M | $298.9M | $296.6M | $237.3M | $157.4M | $146.7M | $136.2M | $120.6M |
| Net income | $181.9M | $73.4M | $168.1M | $285.3M | $272.1M | $140.4M | $229.3M | $96.1M | $126.2M | $76.1M |
| Net margin | 15.0% | 6.0% | 14.5% | 25.1% | 24.6% | 15.1% | 31.0% | 13.5% | 19.6% | 13.5% |
| Diluted EPS | $1.16 | $0.46 | $1.05 | $1.76 | $1.66 | $0.87 | $1.46 | $0.62 | $0.83 | $0.51 |
| EBITDA | $349.2M | $212.2M | $318.4M | $406.2M | $397.7M | $325.0M | $240.2M | $224.9M | $200.6M | $180.6M |
| Operating cash flow | $292.1M | $287.6M | $299.0M | $254.4M | $325.3M | $352.5M | $205.2M | $181.6M | $197.0M | $155.5M |
| Free cash flow | $263.2M | $256.6M | $236.1M | $216.1M | $280.4M | $308.2M | $153.5M | $156.2M | $176.0M | $140.3M |
| Diluted shares | 157.0M | 159.7M | 160.8M | 161.9M | 164.1M | 161.9M | 157.6M | 155.6M | 152.2M | 150.0M |
Balance sheet
| Period end | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $264.7M | $162.2M | $151.8M | $180.6M | $172.6M | $199.1M |
| Short-term investments | $0.00 | $0.00 | $1.1M | $23.7M | $74.5M | $32.5M |
| Total debt | $200.0M | $346.0M | $319.0M | $350.0M | $255.9M | $341.3M |
| Total assets | $2.59B | $2.56B | $2.70B | $2.64B | $2.29B | $2.26B |
| Total liabilities | $478.5M | $639.1M | $635.0M | $672.2M | $593.8M | $691.7M |
| Shareholders' equity | $2.11B | $1.92B | $2.07B | $1.97B | $1.70B | $1.57B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology